NUMAFERM
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.
Press releases
Press
Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides
NUMAFERM makes the production of peptides more efficient
Investment strengthens Evonik’s growth engines Health & Care and Specialty Additives at Evonik
New technical applications are becoming realistic for the first time
Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was made as part of a seed financing round and also includes investments by H
Press
NUMAFERM revolutionizes peptide production and receives seed financing
The Dusseldorf university spin-off NUMAFERM specializes in the biotechnical production of peptides and is able, through its newly developed platform technology, to dramatically reduce costs for this raw material. For the further technological development and an accelerated market entry, NUMAFERM GmbH is now receiving funding in the seven-digit range. High-Tech Gründerfonds (HTGF), Qiagen co-founders and European Business Angels Prof. Detlev Riesner and Dr. Jürgen Schumacher, as well as the Eur
Info & Contact
Address
Merowingerplatz 1a
40225 Düsseldorf
40225 Düsseldorf
In portfolio
28. Apr 2017